Clinical perspective
Updated Urticaria Guidelines Highlight Evolving Approaches to CSU Care
Chronic spontaneous urticaria (CSU) continues to present significant challenges in clinical management, particularly for patients experiencing persistent hives, itching, or angioedema despite treatment. An updated international guideline published in Allergy in 2026 provides an evidence-based framework for diagnosing, assessing, and managing urticaria. Developed through an international collaborative effort involving 210 delegates representing 107 societies across 59 countries, the guideline reflects evolving scientific understanding and therapeutic approaches.
The updated recommendations reinforce the importance of distinguishing between acute and chronic urticaria, as well as spontaneous and inducible forms of the disease. Chronic urticaria is defined by recurring wheals, angioedema, or both for more than six weeks. Accurate classification is essential because different presentations may require different diagnostic approaches. The guideline also emphasizes the importance of distinguishing urticaria from other conditions that can produce similar symptoms, including urticarial vasculitis and certain forms of angioedema.
Assessing disease activity and control remains central to effective CSU management. Validated patient-reported instruments, including the Urticaria Activity Score over seven days (UAS7) and Urticaria Control Test (UCT), help clinicians evaluate symptom severity and treatment response. These assessments can provide a more consistent picture of disease burden, particularly when symptoms fluctuate between appointments. Regular monitoring also supports discussions about whether current treatment is achieving adequate control.
The guideline outlines a structured approach to treatment, beginning with second-generation H1 antihistamines and considering treatment escalation when disease control remains inadequate. The therapeutic landscape is evolving as additional targeted approaches become available, creating new considerations for treatment selection and individualized management. Decisions should account for disease activity, treatment response, safety, patient characteristics, and applicable regulatory approvals.
For healthcare professionals managing CSU, the updated guideline reinforces the importance of systematic assessment, evidence-based treatment decisions, and ongoing evaluation of patient outcomes. As research continues to expand understanding of mast cell-driven inflammation and disease heterogeneity, guideline-directed care provides an important foundation for integrating emerging evidence into clinical practice.
Original research: Zuberbier T, et al. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. 2026.